Landolfi R.Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol1988;5:327.
2.
Landolfi R., Marchioli R., Patrono C.Mechanism of bleeding and thrombosis in myeloproliferative disorders . Thromb Haemost1997;78:617.
3.
Michiels JJ, Kutti J., Stark P., et al. Diagnosis pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med1999;54:46.
4.
Heis N., Rintelen C., Gisslinger B., et al. The effect of interpheron alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol1999;62:27.
5.
Michiels JJErythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost1997;23:441.
6.
Wehmeier A., Daum I., Jamin H., et al. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol1991;63:101.
7.
De Stefano V. , Teofili L., Leone G., et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost1997;23:411.
8.
Denninger MH , Helley D., Valla D., et al. Prospective evaluation of the prevalance of factor V Leiden mutation in portal or hepatic vein thrombosis. Thromb Hemost1997;78:1297.
9.
Tefferi A.Introduction: overview of chronic myeloproliferative patients. Semin Hematol1999;36: 1.
10.
Tefferi A.Pathogenetic mechanisms in chronic myleoproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myleloid metaplasia and chronic myelogenous leukemia. Semin Hematol1999;36:3.
